NCT03401229已完成3 期
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study Of Benralizumab in Patients With Severe Nasal Polyposis
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 413
- 试验地点
- 100
- 主要终点
- Change From Baseline in Total NPS at Week 40
研究概览
简要总结
The aim of this present study is to investigate the use of benralizumab as treatment for severe nasal polyposis. The effect of benralizumab on nasal polyps will be assessed over a 56 weeks of treatment period in patients with severe bilateral nasal polyposis who are still symptomatic despite standard of care therapy, i.e current use of intranasal corticosteroids (INCS) and prior surgery and/or use of systemic corticosteroids. The first 200 patients that complete the 56-week treatment will have a 6 month follow-up (FU) period without dosing.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Capable of giving signed informed consent, which includes compliance with the requirements and restrictions, listed in the informed consent form (ICF) and in protocol.
- •Provision of signed and dated, written informed consent form (ICF) prior to any mandatory study specific procedures, sampling, and analyses and according to international guidelines and/or applicable European Union (EU) guidelines.
- •Provision of signed and dated written genetic informed consent in patients that agree to participate in the genetic sampling, prior to collection of sample for genetic analysis.
- •Female or male patients aged 18 to 75 years inclusive, at the time of signing the ICF.
- •Patients with bilateral sinonasal polyposis that, despite treatment with a stable dose of intranasal corticosteroids (INCS) for at least 4 weeks prior to V1, in addition to history of treatment with systemic (SCS -oral, parenteral) or prior surgery for nasal polyposis (NP), have severity consistent with a need for surgery as described by:
- •A minimum total Nasal Polyp Score (NPS) of 5 out of a maximum score of 8 (with a unilateral score of at least 2 for each nostril) at V1, and continuously maintained at V2 to meet the randomization criterion, as determined by the study Imaging Core Lab;
- •Ongoing symptoms for at least 12 weeks prior to V1;
- •Patient-reported moderate to severe nasal blockage score (NBS) 2 or 3 over the 2-weeks prior to V1 (2-week recall assessment of symptoms, scores 0-none to 3-severe).
- •SNOT-22 total score ≥ 30 at enrolment.
- •Patient must meet the following criteria (points 7-10) at the randomization visit:
- •At least 8 days of evaluable daily diary data in the 14-day period prior to randomization (baseline bi-weekly mean score collected from study Day -13 to study Day 0).
- •At randomization, a bi-weekly mean NBS ≥ 1.
- •SNOT-22 total score ≥ 30 at randomization.
- •At least 70% compliance with INCS during the run-in period based on daily diary.
- •Patients with a minimum weight of 40kg.
- •Negative serum pregnancy test result and a negative urine pregnancy test at randomization for female patients of childbearing potential.
- •Women of childbearing potential (WOCBP) must use an effective form of birth control as defined in the Clinical Study Protocol (CSP).
- •Male subjects who are sexually active must be surgically sterile at least one year prior to Visit 1 or must use an adequate method of contraception (condom or condom with spermicide depending on local regulations) from the first dose of IP until 16 weeks after their last dose. Men with a partner or partners who is (are) not of childbearing potential are exempt of these requirements
排除标准
- •Patients who have undergone any nasal and/or sinus surgery within 3 months prior to V
- •Patients with conditions or concomitant disease that makes them non evaluable for the co-primary efficacy endpoint such as:
- •Unilateral antrochoanal polyps;
- •Nasal septal deviation that occludes at least one nostril;
- •Acute sinusitis, nasal infection, or upper respiratory infection at screening or in the 2 weeks before screening;
- •Current rhinitis medicamentosa;
- •Allergic fungal rhinosinusitis (AFRS) or Allergic fungal sinusitis (AFS);
- •Nasal cavity tumors.
- •Clinically important comorbidities that could confound interpretation of clinical efficacy results including, but not limited to: active upper or lower respiratory tract infection, cystic fibrosis, primary ciliary dyskinesia, eosinophilic diseases other than asthma (e.g. allergic bronchopulmonary aspergillosis/mycosis, eosinophilic granulomatosis with polyangitis [Churg-Strauss syndrome], hypereosinophilic syndromes), granulomatosis with polyangitis (Wegener's granulomatosis), Young's syndrome, etc.
- •Any disorder, including but not limited to: cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator or AstraZeneca and could:
- •Affect the safety of the patient throughout the study;
- •Influence the findings of the studies or their interpretations;
- •Impede the patient's ability to complete the entire duration of study.
- •Patients experiencing an asthma exacerbation requiring systemic (oral and/or parenteral) corticosteroids treatment or hospitalization (>24hrs) for treatment of asthma within 4 weeks prior to V
- •History of anaphylaxis to any biologic therapy or vaccine.
- •Known history of allergy or reaction to any component of the Investigational Product (IP) formulation.
- •History of Guillain-Barré syndrome.
- •A helminth parasitic infection diagnosed within 24 weeks prior to V1 and has not been treated with, or has failed to respond to standard of care therapy.
- •Current malignancy, or history of malignancy, except for: - Patients who have had basal cell carcinoma, localized squamous cell carcinoma of the skin, or in situ carcinoma of the cervix are eligible provided that patient is in remission and curative therapy was completed at least 12 months prior to V1; - Patients who have had other malignancies are eligible provided that the patient is in remission and curative therapy was completed at least 5 years prior to V
- •NOTE: Hormonal therapy is allowed. As long as the cancer is in remission for 5 years, the patient is eligible.
- •Any clinically significant cardiac disease or any electrocardiogram (ECG) abnormality obtained during the screening/run-in period, which may put the patient at risk or interfere with study assessments.
- •Positive hepatitis B surface antigen, or hepatitis C virus antibody serology (confirmed by additional testing, e.g. hepatitis C RNA test, if indicated), or a positive medical history for hepatitis B or C (Note: Patients with history of hepatitis B vaccination without history of hepatitis B are allowed to enroll).
- •History of known immunodeficiency disorder, including a positive human immunodeficiency virus (HIV) test.
- •Infection requiring systemic antibiotics (Ab) within 14 days prior to V1
- •Use of immunosuppressive medication (including but not limited to: methotrexate, troleandomycin, cyclosporine, azathioprine, or any experimental anti-inflammatory therapy) within 3 months prior to V
- •Receipt of any marketed or investigational biologic products (monoclonal or polyclonal antibody) within 6 months or 5 half-lives prior to the date informed consent, is obtained, whichever is longer, prior to V1 and during the study period. This also applies to patients who previously participated in clinical studies and were treated with monoclonal antibodies (e.g. mepolizumab, reslizumab, dupilumab, omalizumab). Note that this restriction do not apply to patients, who are confirmed to have only received treatment with placebo.
- •Previous receipt of benralizumab.
- •Receipt of immunoglobulin or blood products within 30 days prior to V
- •Receipt of live attenuated vaccines 30 days prior to the date of randomization.
- •Receipt of any investigational drug within 30 days or 5 half-lives whichever is longer prior to randomization.
- •Receipt of systemic corticosteroid 4 weeks prior to V1, or a scheduled systemic corticosteroid treatment during the study period.
- •NOTE: Sustained release steroids (e.g. Kenalog [Triamcinolone acetonide]) or depot injections require minimum 6 weeks washout prior to V
- •Receipt of leukotriene antagonist/modifiers for patients who were not on a continuous stable dose for ≥30 days prior to V
- •Concurrent enrolment in another clinical drug interventional trial.
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥ 3 times the upper limit of normal (ULN) confirmed during screening period.
- •Previous randomization in the present study.
- •Planned major surgical procedures or scheduled NP surgery at the time of the study enrolment and randomization.
- •Initiated or is being maintained on an aspirin desensitization regimen for the management of aspirin exacerbated respiratory disease (AERD) at the time of study enrolment or during the run-in period.
- •For women only - currently pregnant (or intend to become pregnant), breastfeeding or lactating.
结局指标
主要结局
Change From Baseline in Total NPS at Week 40
时间窗: Baseline to week 40
Change from baseline in total nasal polyps score (NPS) at week 40 was defined as the endpoint value at week 40 minus the baseline value. The total NPS was the sum of the right and left nostril scores and maximum total NPS is 8, as evaluated by nasal endoscopy and the left and right score were based on central read with scale from 0 to 4 where higher score reflects heavier bilateral nasal polyp burden. Baseline was the last valid value on or prior to the date of randomization. Data collected after nasal polyposis (NP) surgery and/or systemic corticosteroids for NP (SCS_NP) were set to missing. In calculation of summary statistics (mean and standard deviation), the worst-possible (WP) after NP surgery and worst-observation carried forward (WOCF) after SCS_NP were applied. In ANCOVA, a hybrid method of WP after NP surgery, WOCF after SCS_NP and multiple imputation (MI) assuming missing at random were used to build the complete imputation datasets for the analysis.
Change From Baseline in NBS at Week 40
时间窗: Baseline to week 40
Change from baseline in nasal blockage score (NBS) at week 40 was defined as the endpoint value at week 40 minus the baseline value. The NBS was captured by an item in NPSD. Patients were asked to rate the severity of their worst nasal blockage over the past 24 hours using the following response options: 0-none; 1-mild; 2-moderate; 3-severe. The NBS and the changes from baseline were summarized every two weeks (bi-weekly). Baseline was the average of daily responses from Day -13 to Day 1. Data collected after nasal polyposis (NP) surgery and/or systemic corticosteroids for NP (SCS_NP) were set to missing. In calculation of summary statistics (mean and standard deviation), the worst-possible (WP) after NP surgery and worst-observation carried forward (WOCF) after SCS_NP were applied. In ANCOVA, a hybrid method of the WP after NP surgery, WOCF after SCS_NP and multiple imputation (MI) assuming missing at random were used to build the complete imputation datasets for the analysis.
次要结局
- Change From Baseline in SNOT-22 at Week 40(Baseline to week 40)
- Time to First NP Surgery and/or SCS Use for NP to Week 56(Baseline to week 56)
- Time to the First NP Surgery up to Week 56(Baseline to week 56)
- Change From Baseline in DSS at Week 40(Baseline to week 40)
- Change From Baseline in SNOT-22 at Week 56(Baseline to week 56)
- Change From Baseline in DSS at Week 56(Baseline to week 56)
- Change From Baseline in NPS at Week 56(Baseline to week 56)
- Change From Baseline in NBS at Week 56(Baseline to week 56)
- Change From Baseline in LMS at EOT/IPD(Baseline to EOT/IPD, up to 56 weeks)
- Percentage of Subjects With NP Surgery(Baseline to week 56)
- Percentage of Subjects With SCS_NP(Baseline to week 56)
- Percentage of Subjects With NP Surgery or SCS_NP(Baseline to week 56)
- Time to First SCS_NP up to Week 56(Baseline to week 56)
- Total Number of Courses of SCS for NP(Baseline to week 56)
- Total SCS_NP Dose (a) Used (mg)(Baseline to week 56)
- Total Duration of SCS_NP (Days)(Baseline to week 56)
- Annual SCS_NP Use Rate Comparison by Period, Negative Binomial Model(Baseline to week 56)
- Change From Baseline in TSS at Week 40(Baseline to week 40)
- Change From Baseline in Difficulty With Sleeping Due to Nasal Symptoms at Week 40(Baseline to week 40)
- Change From Baseline in Difficulty With Daily Activities Due to Nasal Symptoms at Week 40(Baseline to week 40)
- Change From Baseline in UPSIT Score in Males at Week 40(Baseline to week 40)
- Change From Baseline in UPSIT Score in Females at Week 40(Baseline to week 40)
- Change From Baseline in Sinus Severity Score at EOT/IPD(Baseline to EOT/IPD, up to 56 weeks)
- Change From Baseline in SF-36v2 Physical Component Summary at Week 56(Baseline to week 56)
- Change From Baseline in SF-36v2 Mental Component Summary at Week 56(Baseline to week 56)
- Change From Baseline in SF-36v2 Physical Functioning at Week 56(Baseline to week 56)
- Change From Baseline in SF-36v2 Role Limitations Due to Physical Health at Week 56(Baseline to week 56)
- Change From Baseline in SF-36v2 Bodily Pain at Week 56(Baseline to week 56)
- Change From Baseline in SF-36v2 General Health Perceptions at Week 56(Baseline to week 56)
- Change From Baseline in SF-36v2 Vitality at Week 56(Baseline to week 56)
- Change From Baseline in SF-36v2 Social Functioning at Week 56(Baseline to week 56)
- Change From Baseline in SF-36v2 Role Limitations Due to Emotional Problems at Week 56(Baseline to week 56)
- Change From Baseline in SF-36v2 Mental Health at Week 56(Baseline to week 56)
研究者
研究点 (100)
Loading locations...
相似试验
终止
3 期
A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.Bullous PemphigoidNCT04612790AstraZeneca67
终止
2 期
A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)Chronic Spontaneous UrticariaNCT04612725AstraZeneca159
已完成
3 期
A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABAAsthmaNCT02258542AstraZeneca2,133
终止
3 期
A Study of Benralizumab in Patients With Eosinophilic EsophagitisEosinophilic EsophagitisNCT04543409AstraZeneca211
已完成
3 期
Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent AsthmaAsthmaNCT02322775AstraZeneca211